Navigation Links
Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
Date:3/10/2010

hospital acute care and gastroenterology markets, today announced full year 2009 financial results.

"The approval and launch of Caldolor and our initial public offering made 2009 a pivotal year for Cumberland," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We are pleased to report that we achieved our objectives of remaining profitable and cash flow positive during the Caldolor launch, and that our balance sheet is now the strongest in the history of the Company."

Net Revenue:  For the year ended December 31, 2009, net revenue was $43.5 million, an increase of 24% over the same period in 2008. This growth was due primarily to an increase in volume for Acetadote® (acetylcysteine) Injection, the Company's treatment for acetaminophen overdose, as well as initial stocking from the launch of Caldolor® (ibuprofen) Injection, Cumberland's recently approved IV treatment for pain and fever. Net revenue for the three months ended December 31, 2009 was $10.7 million, compared to $9.8 million for the same period in 2008.

Operating Expenses: &
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... , WARSAW, Ind., Nov. 24 ... today it will be participating in the 21st Annual Piper Jaffray ... 2009, at 8:00 a.m. Eastern Time. , A live ... website at http://investor.zimmer.com . The webcast will be archived ...
... , CARLSBAD, Calif., Nov. 24 Isis Pharmaceuticals, Inc. (Nasdaq: ... will present a company overview at Piper Jaffray,s 21st Annual Health ... at The New York Palace Hotel. , A live audio webcast ... section of the Company,s Web site, www.isispharm.com . A ...
Cached Medicine Technology:
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
(Date:7/9/2014)... School of Medicine of the University of Southern ... specific component of the immune system are completely ... infection. The discovery suggests that blocking this immune ... autoimmune and hyper-inflammatory diseases such as rheumatoid arthritis ... published online on June 23 in The ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... ... ... Tony Rico has recently been promoted to Senior Vice President of Operations at Jackson ... 1, 2009. , , , , ,"This position has been vacant for a ...
... On Tuesday, October 20, 2009, at 1:00 PM Eastern Time/10:00 AM ... (Nasdaq and MTA: CTIC) management team will host an Annual Meeting of ... WA 98119. The meeting will also be webcast live on CTI,s website ... ...
... being stifled by a U.S. law and successful patent challenges ... this week,s issue of the journal Science . ... of Management at the Georgia Institute of Technology, argue in ... challenges -- a provision of the Hatch-Waxman Act of 1984 ...
... After the Austin City Limits music festival concluded, spa ... Austin, Tx. for the 19th annual International SPA Association ... spa community, participated in educational sessions, learned about the ... The Conference theme, "Simplify," resonated with attendees as ...
... National Awareness Campaign to Combat Breast Cancer has been ... Awareness month. The campaign is led by Princess Hessah bint Trad ... wife of the Custodian of the Two Holy Mosques ... bin Abdulaziz. It officially launched on October 10. , As ...
... scientists interested in finance, entrepreneurships and the chemical sciences are ... Medium Business Webinar for an opportunity to learn about trends ... Scheduled for Thursday, Oct. 22, 2 3 p.m. ... of International eChem and author of the well-regarded ICIS "Chemicals ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:Cell Therapeutics, Inc. Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 3Health News:2009 ISPA Conference & Expo Rocks Out With Lance Armstrong in Austin 2
... An APTT-based assay for the detection ... poor anticoagulant response to activated protein C ... an estimation of the anticoagulant function in ... risk associated with inherited and acquired APC ...
Inquire...
Each Uro-Safe® vinyl leg bag is hand-tested for defects through each phase of the manufacturing process and packaged individually in a sterile, easy, peel-open pouch with two latex leg straps....
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: